What is the ASCO Annual Meeting and Why Does It Matter for People With Cancer in 2026?

The American Society of Clinical Oncology (ASCO) holds its Annual Meeting every year in Chicago. This meeting is an opportunity for oncologists and researchers to present results and updates from clinical trials studying new cancer treatments, side effect management, and ways to improve quality of life. Research is also presented about health policy and disparities in cancer treatment.
Why does the ASCO Annual Meeting matter for people with cancer?
The ASCO Annual Meeting is an important conference in oncology. At this meeting, researchers present the latest results from cancer clinical trials. This research can lead to breakthroughs in cancer treatment that could change your care today or in the near future. The results presented at ASCO may lead to new drug approvals, new ways to use already approved treatments, or new treatment techniques.
Following the research news that comes out of the ASCO Annual Meeting can help you stay up-to-date on the latest clinical trial data that could impact your care.
What to expect from HealthTree Foundation during the ASCO Annual Meeting
In addition to providing resources for people with cancer, HealthTree Foundation also conducts research and partners with researchers and institutions. This year, HealthTree Foundation and our research partners will be presenting findings from several of our research programs, including:
- Novel myeloma therapy utilization in digital health advocacy users: A large US cohort analysis of >1,500 patients.
- Artificial intelligence predicted natural killer cell fitness to guide daratumumab and transplant strategies in newly diagnosed multiple myeloma.
- HealthTree survey as an identifier of venous thromboembolism risk mitigation targets in newly diagnosed multiple myeloma.
Easy-to-understand patient summaries of the latest research
Throughout the meeting and after, you can also expect summaries of the most important research coming out of the ASCO Annual Meeting. These summaries will put the research into context and explain the science in easy-to-understand language that will help you know what questions to ask your healthcare team.
Participate in HealthTree research
Join HealthTree and help us find a cure for cancer! Did you know you can participate in HealthTree surveys and research studies when you create an account with HealthTree?
The American Society of Clinical Oncology (ASCO) holds its Annual Meeting every year in Chicago. This meeting is an opportunity for oncologists and researchers to present results and updates from clinical trials studying new cancer treatments, side effect management, and ways to improve quality of life. Research is also presented about health policy and disparities in cancer treatment.
Why does the ASCO Annual Meeting matter for people with cancer?
The ASCO Annual Meeting is an important conference in oncology. At this meeting, researchers present the latest results from cancer clinical trials. This research can lead to breakthroughs in cancer treatment that could change your care today or in the near future. The results presented at ASCO may lead to new drug approvals, new ways to use already approved treatments, or new treatment techniques.
Following the research news that comes out of the ASCO Annual Meeting can help you stay up-to-date on the latest clinical trial data that could impact your care.
What to expect from HealthTree Foundation during the ASCO Annual Meeting
In addition to providing resources for people with cancer, HealthTree Foundation also conducts research and partners with researchers and institutions. This year, HealthTree Foundation and our research partners will be presenting findings from several of our research programs, including:
- Novel myeloma therapy utilization in digital health advocacy users: A large US cohort analysis of >1,500 patients.
- Artificial intelligence predicted natural killer cell fitness to guide daratumumab and transplant strategies in newly diagnosed multiple myeloma.
- HealthTree survey as an identifier of venous thromboembolism risk mitigation targets in newly diagnosed multiple myeloma.
Easy-to-understand patient summaries of the latest research
Throughout the meeting and after, you can also expect summaries of the most important research coming out of the ASCO Annual Meeting. These summaries will put the research into context and explain the science in easy-to-understand language that will help you know what questions to ask your healthcare team.
Participate in HealthTree research
Join HealthTree and help us find a cure for cancer! Did you know you can participate in HealthTree surveys and research studies when you create an account with HealthTree?

about the author
Leslie Fannon Zhang
Leslie Fannon Zhang is a health and science writer and editor who joined HealthTree in 2025. She is passionate about making information about cancer and cancer care as accessible as possible. Leslie has written for the American Society of Clinical Oncology, the American Cancer Society, and the American Association for the Advancement of Science.
More on HealthTree Research
Trending Articles
Get the Latest Enteropathy-Associated Intestinal T-Cell Lymphoma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.
Together we care.
Together we cure.





